Literature DB >> 15064418

SUMO modification of Huntingtin and Huntington's disease pathology.

Joan S Steffan1, Namita Agrawal, Judit Pallos, Erica Rockabrand, Lloyd C Trotman, Natalia Slepko, Katalin Illes, Tamas Lukacsovich, Ya-Zhen Zhu, Elena Cattaneo, Pier Paolo Pandolfi, Leslie Michels Thompson, J Lawrence Marsh.   

Abstract

Huntington's disease (HD) is characterized by the accumulation of a pathogenic protein, Huntingtin (Htt), that contains an abnormal polyglutamine expansion. Here, we report that a pathogenic fragment of Htt (Httex1p) can be modified either by small ubiquitin-like modifier (SUMO)-1 or by ubiquitin on identical lysine residues. In cultured cells, SUMOylation stabilizes Httex1p, reduces its ability to form aggregates, and promotes its capacity to repress transcription. In a Drosophila model of HD, SUMOylation of Httex1p exacerbates neurodegeneration, whereas ubiquitination of Httex1p abrogates neurodegeneration. Lysine mutations that prevent both SUMOylation and ubiquitination of Httex1p reduce HD pathology, indicating that the contribution of SUMOylation to HD pathology extends beyond preventing Htt ubiquitination and degradation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064418     DOI: 10.1126/science.1092194

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  277 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  An in vitro Förster resonance energy transfer-based high-throughput screening assay for inhibitors of protein-protein interactions in SUMOylation pathway.

Authors:  Yang Song; Jiayu Liao
Journal:  Assay Drug Dev Technol       Date:  2011-12-22       Impact factor: 1.738

Review 3.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

4.  Mass spectrometric identification of novel posttranslational modification sites in Huntingtin.

Authors:  Gaofeng Dong; Eduardo Callegari; Christian J Gloeckner; Marius Ueffing; Hongmin Wang
Journal:  Proteomics       Date:  2012-06       Impact factor: 3.984

Review 5.  Cardiac function and disease: emerging role of small ubiquitin-related modifier.

Authors:  Jun Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

Review 6.  Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.

Authors:  Ronald Wetzel
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

7.  Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy.

Authors:  Robert G Mealer; Alexandra J Murray; Neelam Shahani; Srinivasa Subramaniam; Solomon H Snyder
Journal:  J Biol Chem       Date:  2013-12-09       Impact factor: 5.157

8.  SUMOylation attenuates sensitivity toward hypoxia- or desferroxamine-induced injury by modulating adaptive responses in salivary epithelial cells.

Authors:  Ha-Van Nguyen; Jo-Lin Chen; Jenny Zhong; Kwang-Jin Kim; Edward D Crandall; Zea Borok; Yuan Chen; David K Ann
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

9.  SUMO-conjugating enzyme E2 UBC9 mediates viral immediate-early protein SUMOylation in crayfish to facilitate reproduction of white spot syndrome virus.

Authors:  An-Jing Chen; Lu Gao; Xian-Wei Wang; Xiao-Fan Zhao; Jin-Xing Wang
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  Probing the Huntingtin 1-17 membrane anchor on a phospholipid bilayer by using all-atom simulations.

Authors:  Sébastien Côté; Vincent Binette; Evgeniy S Salnikov; Burkhard Bechinger; Normand Mousseau
Journal:  Biophys J       Date:  2015-03-10       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.